Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.41 USD
+0.01 (0.12%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $8.41 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Theravance Biopharma, Inc. [TBPH]
Reports for Purchase
Showing records 101 - 120 ( 210 total )
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Home With Theravance,Perspectives on TD-0903 for Treating ALI in Hospitalized COVID-19 Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Theravance Doses First Patient in TD-0903 Phase 2 for Acute Lung Injury Due to Covid-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
First Subject Dosed in TD-0903''s Phase 1 Study to Address Acute Lung Injury Due to Covid-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Deploying Well Established Lung Expertise to Address Covid-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department